Charles River Laboratories Intl. Inc vs Extra Space Storage, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Extra Space Storage, Inc. trades at $134.65 (market cap $28.12B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Extra Space Storage, Inc. for 109 Days on average.
| CRL | EXR | |
|---|---|---|
Market Cap | $14.23B | $28.12B |
Volume | 1,176,885 | 2,595,579 |
Sector | Health | Real Estate |
52-Week High | $310.77 | $152.85 |
52-Week Low | $149.93 | $126.67 |
Typical Hold Time | 33 Days | 109 Days |
Enterprise Value | $17.06B | $41.84B |
Dividend Yield | — | 4.87% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
Extra Space Storage (EXR) trades at $133.12, up 1.08% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38 billion in 2025, and net income margin remains healthy at 27.79%. Analyst consensus is evenly split between Buy and Hold, with a price target of $158.33 implying upside potential. Recent news highlights leadership transition and institutional buying interest.
EXR presents a balanced risk-reward profile. Upside is supported by steady demand, dividend payments, and analyst targets, but risks include high leverage, interest rate sensitivity, and a bearish technical trend. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels. Investors should weigh solid fundamentals against macroeconomic headwinds affecting REITs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →